Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
- 294 Downloads
Based on the results of the PROWESS trial the European Agency for the Evaluation of Medicinal Products has recently approved drotrecogin alfa (activated) for treatment of adult patients with severe sepsis and multiple-organ failure. We report study's data on efficacy and safety in patients with multiple-organ dysfunction.
Design and setting
Randomized, double-blind, placebo-controlled, multicenter trial in 164 medical centers.
1271 patients (75.2% of the intention-to-treat population, n=1690) with multiple-organ dysfunction at study entry.
Drotrecogin alfa (activated) n=634, 24 µg/kg per hour for 96 h or placebo (n=637).
Observed 28-day mortality was significantly lower with drug treatment than with placebo (26.5%vs. 33.9%), cardiovascular and respiratory organ dysfunction resolved more rapidly over the first 7 days, and serious bleeding events were more frequent (2.4% vs. 1.3%).
Treatment with drotrecogin alfa (activated) significantly reduced 28-day mortality and more quickly resolved cardiovascular and respiratory organ dysfunction. The difference in serious bleeding event rates may be clinically significant; however, the overall benefit-risk profile appears favorable.
KeywordsDrotrecogin alfa (activated) Activated protein C Xigris Recombinant proteins Sepsis Septic shock
The investigation would not have been possible without the effort of the product development team at Eli Lilly and Company. We are indebted to Samiha Sarwat for providing statistical analysis assistance. This study was sponsored by a grant from Eli Lilly and Company, Indianapolis, Ind., USA. J.-F. D had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
- 5.Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644PubMedGoogle Scholar
- 7.Davies, A, Green, C, Hutton, J, Chinn, C (2001) Severe sepsis: a European estimate of the burden of disease in ICU. Intensive Care Med 27:S284Google Scholar
- 15.Bajzar L (2000) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20:2511–2518Google Scholar
- 21.Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834–840Google Scholar
- 25.Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710CrossRefPubMedGoogle Scholar
- 26.Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M (2001) Scientific and standardization committee communications: towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Available online at: http://www.med.unc.edu/isth/dicdef.htm. Accessed January 15:2002Google Scholar
- 28.Breslow NE, Day NE (1980) Statistical methods in cancer research, vol I. IARC, Lyon, pp 5–338Google Scholar
- 31.Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005–2009Google Scholar
- 32.Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Nakao S (2001) An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 29:1164–1168PubMedGoogle Scholar
- 35.Suzuki K, Nishioka J, Kusumoto H, Hashimoto S (1984) Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem (Tokyo) 95:187–195Google Scholar